<sup>18</sup>F-FDG PET/CT代谢参数及异质性指数与胃癌临床病理特征之间的关系-东南大学学报医学版

¹⁸F-FDG PET/CT代谢参数及异质性指数与胃癌临床病理特征之间的关系

作者：李响何健

单位：南京大学医学院附属鼓楼医院核医学科, 江苏南京 210008

分类号：R735.2

出版年·卷·期（页码）：2024·43·第一期（111-117）

摘要：

目的: 探究¹⁸F-氟脱氧葡萄糖(FDG) PET/CT代谢参数及异质性指数(HI)与胃癌临床病理特征之间的关系。方法: 回顾性分析74例经病理证实的胃腺癌患者的¹⁸F-FDG PET/CT资料及临床病理资料。测量原发灶最大标准化摄取值(SUV_max)、平均标准摄取值(SUV_mean)、肿瘤代谢体积(MTV)、总糖酵解量(TLG)、HI。HI-1为感兴趣区内SUV值的变异系数(CV),HI-2为不同SUV_max阈值下MTV值的线性回归斜率的绝对值。运用Spearman秩相关及Logistic回归分析,评估上述参数与胃癌临床病理特征之间的相关性。结果: 标准摄值(SUV)及HI在不同分化程度的胃癌中差异具有统计学意义(P<0.01),分化程度与SUV_max及HI-1均呈中度正相关(r值分别为0.32、0.39,均P<0.05)。含有低黏附细胞成分胃癌的SUV及HI-1均较低(P<0.05)。总糖酵解量(TLG) ≥ 57.5 g为Ⅳ期胃癌的独立危险因素[OR: 6.089(1.08,34.33)]。结论: ¹⁸F-FDG PET/CT代谢参数及HI可反映部分胃癌临床及病理信息。

Objective: To investigate the relationship between¹⁸F-FDG PET/CT metabolic parameters and heterogeneity index(HI) and the clinicopathological features of gastric cancer. Methods: The ¹⁸F-FDG PET/CT and clinicopathological data of 74 patients with pathologically confirmed gastric adenocarcinoma were retrospectively analyzed. Maximum standardized uptake value (SUV_max),mean standardized uptake value (SUV>sub>mean),tumor metabolic volume (MTV),total glycolysis volume (TLG),and HI were measured in the primary foci.HI-1 was the coefficient of variation (CV) of SUV values within the region of interest,and HI-2 was the absolute value of linear regression slopes of the MTV values at different SUV_max thresholds. Spearman's rank correlation and Logistic regression analysis were used to assess the correlation between the above parameters and clinicopathologic features of gastric cancer. Results: SUV value and HI were significantly different in gastric cancers with different degrees of differentiation (P<0.01),and the degree of differentiation was moderately positively correlated with both SUV_max and HI-1 (r=0.32,0.39,all P<0.05). The SUV value and HI-1 were lower in gastric cancers containing low adherent cell components (P<0.05).TLG ≥ 57.5 g was an independent risk factor for stage Ⅳ gastric cancer[OR:6.089 (1.08,34.33)].Conclusion: ¹⁸F-FDG PET/CT metabolic parameters and HI reflect clinical and pathological information of some gastric cancers.

参考文献：

[1] CAO W,CHEN H D,YU Y W,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl),2021,134(7):783-791.
[2] GULLO I,CARNEIRO F,OLIVEIRA C,et al.Heterogeneity in gastric cancer:from pure morphology to molecular classifications[J].Pathobiology,2018,85(1-2):50-63.
[3] FENG F,LIU J,WANG F,et al.Prognostic value of differentiation status in gastric cancer[J].BMC Cancer,2018,18(1):865.
[4] 汤敏敏,尤阳,李夏黎,等.肺神经内分泌肿瘤的临床病理特征及18F-FDG PET/CT影像表现分析[J].中华核医学与分子影像杂志,2021,41(5):262-267.
[5] 李洋洋,郭喆,李天女,等.原发纵隔大B细胞淋巴瘤的18F-FDGPET/CT显像表现[J].中华核医学与分子影像杂志,2020,40(1):1-5.
[6] 王彤,孙洪赞,张军.对比PET-CT与MRI对宫颈癌淋巴结转移诊断价值的Meta分析[J].现代医学,2020,48(6):705-710.
[7] GONG C,LIU C,TAO Z,et al.Temporal heterogeneity of HER2 expression and spatial heterogeneity of (18)F-FDG uptake predicts treatment outcome of pyrotinib in patients with HER2-positive metastatic breast cancer[J].Cancers (Basel),2022,14(16):3973.
[8] XIE Y,LIU C,ZHAO Y,et al.Heterogeneity derived from (18) F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients[J].Cancer Med,2022,11(9):1948-1955.
[9] 顾丙新,谢一兆,王碧芸,等.治疗前18F-FDG PET/CT摄取异质性在HER2阳性转移性乳腺癌疗效预测中的价值[J].中华核医学与分子影像杂志,2021,41(2):76-81.
[10] LIU X,WANG S C,NI M,et al.Correlation between (18)F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer[J].Abdom Radiol (NY),2022,47(4):1255-1264.
[11] NAGTEGAAL I D,ODZE R D,KLIMSTRA D,et al.The 2019 WHO classification of tumours of the digestive system[J].Histopathology,2020,76(2):182-188.
[12] MARIETTE C,CARNEIRO F,GRABSCH H I,et al.Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma[J].Gastric Cancer,2019,22(1):1-9.
[13] TAO J,ZHANG Y,WANG T.Potential role of glucose transporter-1 expression in gastric cancer:a Meta-analysis and systematic review[J].Iran J Public Health,2020,49(11):2044-2053.
[14] BALAKRISHNAN K,GANESAN K.Occurrence of differing metabolic dysregulations,a glucose driven and another fatty acid centric in gastric cancer subtypes[J].Funct Integr Genomics,2020,20(6):813-824.
[15] MARIETTE C,CARNEIRO F,GRABSCH H I,et al.Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma[J].Gastric Cancer,2019,22(1):1-9.
[16] LIU S,QIAO X,JI C,et al.Gastric poorly cohesive carcinoma:differentiation from tubular adenocarcinoma using nomograms based on CT findings in the 40s late arterial phase[J].Eur Radiol,2021,31(8):5768-5778.
[17] DRUBAY V,NUYTENS F,RENAUD F,et al.Poorly cohesive cells gastric carcinoma including signet-ring cell cancer:updated review of definition,classification and therapeutic management[J].World J Gastrointest Oncol,2022,14(8):1406-1428.
[18] 王建林,丁晓芳,马晚俊,等.¹⁸F-FDG PET/CT代谢参数及代谢异质性与胃癌临床病理特征的相关性[J].中国临床医学影像杂志,2022,33(6):414-418,429.
[19] 周锦,张漫雪,胡秀芝,等.原发胃癌¹⁸F-FDG PET/CT代谢参数与临床病理特征的相关性[J].中国医学影像技术,2019,35(1):95-99.
[20] JIANG M,WU N,XU B,et al.Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis[J].Theranostics,2019,9(18):5359-5373.
[21] GAO J,SONG J,ZHANG Y,et al.CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation[J].Acta Biochim Biophys Sin (Shanghai),2022,54(5):752-755.
[22] JAYAPRAKASAM V S,PARODER V,SCHODER H.Variants and pitfalls in PET/CT imaging of gastrointestinal cancers[J].Semin Nucl Med,2021,51(5):485-501.
[23] LIU G,YIN H,CHENG X,et al.Intra-tumor metabolic heterogeneity of gastric cancer on (18)F-FDG PETCT indicates patient survival outcomes[J].Clin Exp Med,2021,21(1):129-138.
[24] 韩亚峰,刘红,高小华.胃癌患者多层螺旋CT影像学表现与临床特征的关系[J].癌症进展,2022,20(21):2249-2251,2258.《东南大学学报(医学版)》唯一公共邮箱:bjb@pub.seu.edu.cn

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录